Introduction: In this paper we propose a novel method for developing a polymeric heart valve that could potentially offer an optimum solution for a heart valve substitute. The valve design proposed will provide superior hydrodynamic performance and excellent structural integrity. A full description of the design process is given together with an analysis of the hemodynamic performance using a 2-way strongly coupled Fluid Structure Interaction (FSI).
Method: A polymeric tri-leaflet heart valve is designed based on a patient's sinus of Valsalva (SOV) geometry. The design strategy aims to improve valve hemodynamic performance as well as valve durability by avoiding stress concentrations in the leaflets and reducing the maximum stress level. The valve dynamics and stress levels are also validated by comparing the predicted data to existing experimental and numerical data.
Results: The stress distribution in the valve structure is fully characterized throughout the simulation and Von Mises stress is found to be up to 5.32 Mpa during diastole. The results show that an effective orifice area (EOA) and a pressure drop of 3.22 cm^2, and 3.52 mmHg, respectively, can be achieved using the proposed design.
Conclusions: The optimized valve demonstrates high hemodynamic performance with no sign of damaging stress concentration in the entire cardiac cycle.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5301/ijao.5000413 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of kidney volume on incidence of in-hospital kidney-related adverse outcomes in patients with acute heart failure.
BMC Cardiovasc Disord
January 2025
Graduate School of Public Health, St Luke's International University, Tokyo, Japan.
Background: Recent studies revealed an association between small kidney volume and progression of kidney dysfunction in particular settings such as kidney transplantation and transcatheter aortic valve implantation. We hypothesized that kidney volume was associated with the incidence of kidney-related adverse outcomes such as worsening renal function (WRF) in patients with acute heart failure (AHF).
Methods: This study was a single-center retrospective cohort study.
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia.
Mol Diagn Ther
January 2025
Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, 4288A-1151 Richmond Street North, London, ON, N6A 5B7, Canada.
Clinical endpoints caused by hyperlipoproteinemia include atherosclerotic cardiovascular disease and acute pancreatitis. Emerging lipid-lowering therapies targeting proprotein convertase subtilisin/kexin 9 (PCSK9), lipoprotein(a), apolipoprotein C-III, and angiopoietin-like protein 3 represent promising advances in the management of patients with hyperlipoproteinemia. These therapies offer novel approaches for lowering pathogenic lipid and lipoprotein species, particularly in patients with serious perturbations who are not adequately controlled with conventional treatments or who are unable to tolerate them.
View Article and Find Full Text PDFNon-bacterial thrombotic endocarditis in a patient with high-grade serous ovarian carcinoma: diagnostic challenges and management insights.
BMJ Case Rep
January 2025
Cardiology, East Cheshire NHS Trust, Macclesfield, UK.
Non-bacterial thrombotic endocarditis (NBTE) is characterised by sterile vegetations on heart valves and often emerges in hypercoagulable states like malignancy. It is frequently underdiagnosed and only comes to light during postmortem examination. Early diagnosis and treatment with anticoagulation can help lower mortality.
View Article and Find Full Text PDFA Novel Staging System of Cardiac Damage in Aortic Stenosis based on Multi-Chamber Myocardial Deformation.
Eur Heart J Cardiovasc Imaging
January 2025
Department of Cardiology, Istituto Auxologico Italiano, IRCCS, Milan, Italy.
Aims: This study evaluates whether multi-chamber myocardial deformation analysis using speckle tracking echocardiography (STE) can enhance validated current staging systems and improve risk stratification for patients with moderate-to-severe aortic stenosis (AS).
Methods And Results: We reanalyzed 2D, Doppler, and STE data obtained from two cohorts: derivation (654 patients, median age: 82 years; 51% men) and validation (237 patients, median age: 77 years; 55% men) with at least moderate AS (aortic valve area<1.5 cm2).
Tricuspid regurgitation and outcomes in mitral valve transcatheter edge-to-edge repair.
Eur Heart J
January 2025
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Background And Aims: The association between periprocedural change in tricuspid regurgitation (TR) and outcomes in patients undergoing mitral transcatheter edge-to-edge repair (M-TEER) is unclear. This study aimed to examine the prognostic value of TR before and after M-TEER.
Methods: Patients in the OCEAN-Mitral registry were divided into four groups according to baseline and post-procedure echocardiographic assessments: no TR/no TR (no TR), no TR/significant TR (new-onset TR), significant TR/no TR (normalized TR), and significant TR/significant TR (residual TR) (all represents before/after M-TEER).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!